Skip to main content

Table 1 Characteristics and disease variables in JDM patients and controls

From: Bone mineral density and explanatory factors in children and adults with juvenile dermatomyositis at long term follow-up; a cross sectional study

  All participants Age < 20y Age ≥ 20y
Patients (n = 59)a Controls (n = 59)a Patients (n = 28) Controls n = 28 Patients (n = 31) Controls n = 31
Age, y, median (range) 21.5 (6.7–55.4) 21.6 (6.2–55.4) 15.3 (6.7–19.8) 14.4 (6.2–20.1) 34.3 (20.4–55.4) 34.2 (20.5–55.4)
Female, n (%) 36 (61) 36 (61) 20 (71.4) 20 (71.4) 16 (51.6) 16 (51.6)
BMI, kg/m2, mean (SD) 22.3 (4.8) 22.7 (4.5) NA NA 24.0 (4.4) 23.8 (3.5)
Weight, kg, mean (SD) 62.6 (20.1) 65.5 (20.1) 52.0 (19.5) 57.0 (22.7) 72.1 (15.7) 73.2 (13.6)
Height, cm, mean (SD) 164.9 (14.7)† 167.3 (15.8) 157.1 (15.9) 159.8 (18.3) 171.8 (9.1) 174.0 (9.2)
Disease duration, y, median (IQR) 16.8 (6.6–27.0) NA 6.5 (4.9–8.7) NA 26.3 (18.9–31.0) NA
Time from diagnosis to medication, month, median (IQR) 4 (2.0–6.25) NA 4 (1.8–6.3) NA 4 (2.0–7.5) NA
Fracture any, n (%) 19 (32.2) 21 (36.8) 7 (25.0) 7 (25.0) 21 (67.7) 14 (48.3)
PRINTO inactive, n (%) 21 (35.6) NA 9 (32.1) NA 12 (38.7) NA
DAS (0–20) at follow up, median (IQR) 5 (3.0–6.0) NA 5 (2.2–6.0) NA 4.5 (3.0–7.0) NA
DAS at diagnosis (0–20), median (IQR) 13.0 (9.0–15.0) NA 13.0 (9.6–15.0) NA 13.0 (9.0–16.0) NA
MDI total (0–40) at follow up, median (IQR) 3 (2–6) NA 2 (1–4) NA 5 (3–8) NA
MDI osteoporosis, n (%) 5 (8.5) NA 2 (7.1) NA 3 (9.7) NA
Smoking daily, n (%) 11 (18.6) 8 (13.6) 3 (10.7) 2 (7.1) 8 (13.6) 6 (19.1)
SF 36 physical component score ≥ 20y, median (IQR) NA NA NA NA 52.2 (42.4–57.7)† 56.5 (52.8–59.6)
Exercise ≥2 h/week ≥20y, n (%) NA NA NA NA 19 (61.3) 20 (64.5)
Exercise ≥2 activities/week ≥20 y, n (%) NA NA NA NA 14 (45.2) 19 (61.3)
  1. BMI body mass index, DAS disease activity score, MDI myositis damage index, RINTO paediatric rheumatology international trials organisation, NA not applicable, aIn each age group n = 59 otherwise stated as n ≥ 20y = 31 and n < 20y =28). †p < 0.05. p-values when comparing patients and controls using paired sample (2-tailed) or chi-square tests when appropriate